Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Lung Cancer Non-small Cell Stage IV
Interventions
DRUG

Almonertinib

"Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off."

Trial Locations (2)

200032

Zhongshan hospital, Shanghai

361003

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

The First Affiliated Hospital of Xiamen University

OTHER

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06463171 - Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter